NGS data of CRISPR/dCas9 activation screen with CDK4/6 inhibitor Palbociclib in bladder cancer

Published: 1 June 2020| Version 3 | DOI: 10.17632/ptx3dzs926.3
Zhichao Tong


We used a genome-scale functional genomics approach to determine the mechanisms of resistance to PD0332991. Transcriptional activation was performed using the synergistic activation mediator (SAM) CRISPR-dCas9 library. Work flow: a) T24 cells with stably transduced SAM components. b) Low MOI lentiviral transduction of amplified sgRNA library. c)antibiotic selection for transduced cells. e) divide cells into control(vehicle) and PD 7 days treatment. f) NGS of PCR amplicons. g) Comparison of sgRNA counts in control and treatment conditions.